IL28B基因多態(tài)檢測(cè)，開創(chuàng)丙肝個(gè)體化治療的新紀(jì)元
l IL28B基因多態(tài)性位點(diǎn)的檢測(cè)，開創(chuàng)了丙肝個(gè)體化治療的新紀(jì)元(1-2)l IL28B基因多態(tài)位點(diǎn)rs12979860和rs8099917的基因多態(tài)性是影響HCV感染及其標(biāo)準(zhǔn)化治療最重要的影響因素(3-4)。 l IL28B基因多態(tài)性對(duì)丙肝感染后的自愈，IFN＋RBV的標(biāo)準(zhǔn)治療方案的治療效果預(yù)測(cè)(5-6)， l 還是新一代的丙肝治療藥物蛋白酶抑制劑的治療效果和治療療程的決策，均有重大的臨床價(jià)值(7-8)， l 其價(jià)值超過(guò)公認(rèn)的丙肝基因分型檢測(cè)(9)。 l 2011年美國(guó)肝臟病學(xué)會(huì)已將其檢測(cè)列入其丙肝的治療指南(9,10)。l 中山大學(xué)附屬第五醫(yī)院提供國(guó)際上首創(chuàng)的IL28B基因多態(tài)快速檢測(cè)標(biāo)準(zhǔn)手段，為醫(yī)生和患者治療決策提供準(zhǔn)確的科學(xué)依據(jù)(11－12)。參考文獻(xiàn)Shawn P. et al. Genomics: Hepatitis C virus gets personal. Nature 2009;461, 357-358 Wapner J. Pharmacogenomics. Gene variants affect hepatitis C treatment, but link is elusive.Science. 2010 ;330(6004):579.Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, et al.Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV,et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010;139:120-129. 30. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010;139:821-827. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-1104. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-1109. GHANY ET AL. An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases Hepatology 2011 1433-1444 EASL Clinical Practice Guidelines: Management of hepatitis C virus infection Journal of Hepatology 2011 vol. 55 j 245–264Song JW et al. Development and Preliminary Clinical Evaluation of an Novel Biosensor-based Microarray (BBM) Assay For Detection of Rs8099917 And Rs12979860 For HCV Individual Therapy Gastroenterology 2012 142(S1),S-944Li PY, et al. A novel biosensor-based microarray assay for detecting rs8099917 and rs12979860 genotypes. World J Gastroenterol 2012 November 28; 18(44): -0000
